ATE360000T1 - Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung - Google Patents

Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung

Info

Publication number: ATE360000T1
Authority: AT; Austria
Prior art keywords: dihydroxy; vitamin; alpha; sub; oxime
Prior art date: 2001-10-12

Application number

AT02767010T

Other languages

English (en)

Inventor

Gary H Posner

Jay A White

Glenville Jones

Bethany Halford

Mehmet Kahraman

Heung Bae Jeon

Original Assignee

Univ Johns Hopkins

Cytochroma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-12

Filing date

2002-10-11

Publication date

2007-05-15

2002-10-11 Application filed by Univ Johns Hopkins, Cytochroma Inc filed Critical Univ Johns Hopkins

2007-05-15 Application granted granted Critical

2007-05-15 Publication of ATE360000T1 publication Critical patent/ATE360000T1/de

Links

-1 OXIME ANALOGUE OF 1-ALPHA,25-DIHYDROXY-VITAMIN-D3 Chemical class 0.000 title 1
230000000125 calcaemic effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102100027518 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Human genes 0.000 abstract 1
101000861278 Homo sapiens 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Hematology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Nutrition Science (AREA)
Pulmonology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT02767010T 2001-10-12 2002-10-11 Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung ATE360000T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US32842801P	2001-10-12	2001-10-12

Publications (1)

Publication Number	Publication Date
ATE360000T1 true ATE360000T1 (de)	2007-05-15

Family

ID=23280940

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02767010T ATE360000T1 (de)	2001-10-12	2002-10-11	Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung

Country Status (11)

Country	Link
US (1)	US6982258B2 (de)
EP (1)	EP1436257B1 (de)
JP (1)	JP4436674B2 (de)
AT (1)	ATE360000T1 (de)
CA (1)	CA2463505C (de)
CY (1)	CY1106638T1 (de)
DE (1)	DE60219655T2 (de)
DK (1)	DK1436257T3 (de)
ES (1)	ES2283593T3 (de)
PT (1)	PT1436257E (de)
WO (1)	WO2003031400A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6242434B1 (en)	1997-08-08	2001-06-05	Bone Care International, Inc.	24-hydroxyvitamin D, analogs and uses thereof
US6087350A (en) *	1997-08-29	2000-07-11	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AU7895601A (en)	2000-07-18	2002-01-30	Bone Care Int Inc	Stabilized 1alpha-hydroxy vitamin d
US20050059641A1 (en) *	2003-06-17	2005-03-17	Aphios Corporation	Compositions and methods for treating and preventing cancer using analogs of vitamin D
US20050192255A1 (en) *	2003-07-30	2005-09-01	Jin Tian	Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
JP2007537263A (ja) *	2004-05-10	2007-12-20	ノバセアインコーポレイティッド	活性ビタミンｄ化合物による動脈再狭窄の予防法
US7094775B2 (en)	2004-06-30	2006-08-22	Bone Care International, Llc	Method of treating breast cancer using a combination of vitamin D analogues and other agents
WO2006032299A1 (en) *	2004-09-24	2006-03-30	Susanna Miettinen	Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2006074227A2 (en) *	2005-01-04	2006-07-13	Johns Hopkins University	HIGHLY ANTIPROLIFERATIVE, LOW-CALCEMIC, ANALOGS OF THE HORMONE 1α, 25-DIHYDROXYVITAMIN D3 WITH CARBONYL SIDE CHAINS
WO2006113990A2 (en) *	2005-04-25	2006-11-02	Cytochroma Inc.	LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1α ,25-DIHYDROXY VITAMIN D3
CA2624897C (en) *	2005-10-12	2017-02-14	Proventiv Therapeutics, Llc	Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
ES2593047T3 (es)	2006-02-03	2016-12-05	Opko Renal, Llc	Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
ES2670029T3 (es)	2006-06-21	2018-05-29	Opko Ireland Global Holdings, Ltd.	Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
EP2144872A2 (de) *	2007-04-18	2010-01-20	Johns Hopkins University	Gering kalzämische und hoch antiproliferative calcitriol-analoga
KR20190028822A (ko)	2007-04-25	2019-03-19	사이토크로마 인코포레이티드	비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US8592401B2 (en) *	2007-04-25	2013-11-26	Proventiv Therapeutics, Llc	Methods and compounds for vitamin D therapy
HUE073014T2 (hu)	2007-04-25	2025-12-28	Opko Renal Llc	Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén
US11752158B2 (en) *	2007-04-25	2023-09-12	Eirgen Pharma Ltd.	Method of treating vitamin D insufficiency and deficiency
US20100048913A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110118219A1 (en)	2008-03-25	2011-05-19	University Of Maryland, Baltimore	Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
EP2281058B1 (de)	2008-04-02	2016-06-29	Opko Ireland Global Holdings, Ltd.	Verfahren, zusammensetzungen, verwendungen und kits mit eignung bei vitamin-d-mangel und verwandten störungen
CN102686600A (zh)	2009-02-05	2012-09-19	托凯药业股份有限公司	甾体cyp17抑制剂/抗雄激素物质的新型药物前体
US20100227414A1 (en) *	2009-03-05	2010-09-09	Trex Enterprises Corp.	Affinity capture mass spectroscopy with a porous silicon biosensor
US9775903B2 (en) *	2010-01-13	2017-10-03	Johns Hopkins University	1-deoxy analogs of 1,25-dihydroxyvitamin D3 compounds
WO2011123476A1 (en)	2010-03-29	2011-10-06	Cytochroma Inc.	Methods and compositions for reducing parathyroid levels
RU2015137617A (ru)	2013-03-14	2017-04-18	Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер	Агенты, подавляющие андрогенные рецепторы, и их применение
KR101847947B1 (ko)	2013-03-15	2018-05-28	옵코 아이피 홀딩스 Ⅱ 인코포레이티드	안정화되고 변형된 비타민 ｄ 방출 제형
CN105636594A (zh)	2013-08-12	2016-06-01	托凯药业股份有限公司	使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
US10220047B2 (en)	2014-08-07	2019-03-05	Opko Ireland Global Holdings, Ltd.	Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104557647B (zh) *	2015-01-13	2016-07-06	南京理工大学	维生素d肟类衍生物、合成方法及其应用
CN104945296B (zh) *	2015-06-09	2016-08-24	南京理工大学	一类芳香醛腙修饰的维生素d2衍生物、合成及其应用
JP7032322B2 (ja)	2016-03-28	2022-03-08	オプコアイルランドグローバルホールディングスリミテッド	ビタミンｄ治療法
CN117003679A (zh) *	2022-04-29	2023-11-07	南澳大利亚大学	新型抑制剂化合物
WO2025094144A1 (en)	2023-11-02	2025-05-08	Eirgen Pharma Ltd.	Controlling loss of kidney function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4481198A (en) *	1984-02-13	1984-11-06	Wisconsin Alumni Research Foundation	Vitamin D metabolism inhibitor
GB9623569D0 (en) *	1996-11-13	1997-01-08	Immunodiagnostic Systems Ltd	Vitamin D immumoassay systems

2002
- 2002-10-11 ES ES02767010T patent/ES2283593T3/es not_active Expired - Lifetime
- 2002-10-11 WO PCT/CA2002/001519 patent/WO2003031400A1/en not_active Ceased
- 2002-10-11 AT AT02767010T patent/ATE360000T1/de active
- 2002-10-11 CA CA2463505A patent/CA2463505C/en not_active Expired - Lifetime
- 2002-10-11 EP EP02767010A patent/EP1436257B1/de not_active Expired - Lifetime
- 2002-10-11 DK DK02767010T patent/DK1436257T3/da active
- 2002-10-11 PT PT02767010T patent/PT1436257E/pt unknown
- 2002-10-11 DE DE60219655T patent/DE60219655T2/de not_active Expired - Lifetime
- 2002-10-11 JP JP2003534384A patent/JP4436674B2/ja not_active Expired - Fee Related
- 2002-10-15 US US10/270,158 patent/US6982258B2/en not_active Expired - Lifetime
2007
- 2007-06-04 CY CY20071100741T patent/CY1106638T1/el unknown

Also Published As

Publication number	Publication date
DE60219655D1 (de)	2007-05-31
PT1436257E (pt)	2007-05-31
ES2283593T3 (es)	2007-11-01
CA2463505C (en)	2011-07-12
WO2003031400A1 (en)	2003-04-17
EP1436257B1 (de)	2007-04-18
DK1436257T3 (da)	2007-06-25
EP1436257A1 (de)	2004-07-14
JP4436674B2 (ja)	2010-03-24
DE60219655T2 (de)	2007-12-27
JP2005536444A (ja)	2005-12-02
US20030171342A1 (en)	2003-09-11
CY1106638T1 (el)	2012-01-25
CA2463505A1 (en)	2003-04-17
US6982258B2 (en)	2006-01-03

Legal Events

Date

Code

Title

Description

2007-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1436257

Country of ref document: EP

Publication	Publication Date	Title
ATE360000T1 (de)	2007-05-15	Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung
AR026173A1 (es)	2003-01-29	Inhibidores de neuraminidasas.
ES2139943T3 (es)	2000-02-16	Nuevos inhibidores de la sintasa de prostaglandina.
EA200301216A1 (ru)	2004-06-24	Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
NO20031687D0 (no)	2003-04-11	Veksthormonsekretagoger
DK1474406T3 (da)	2007-07-23	Disubstituerede thiazolylcarboxanilider samt deres anvendelse som mikrobicider
BRPI0410081A (pt)	2006-05-16	composto, composição farmacêutica, método de tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
ATE232873T1 (de)	2003-03-15	Phosphonsaürederivate als ptp-1b-inhibitoren
DK0863891T3 (da)	2003-03-17	(Methylsulfonyl)phenyl-2-(5H)-furanoner som COX2-inhibitorer
BRPI0415288A (pt)	2006-12-19	composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto
BR9907300A (pt)	2000-10-24	Inibidores do fator xa oxoaza-heterociclila substituìdos
DK0705254T3 (da)	1999-01-25	Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
ES2184070T3 (es)	2003-04-01	Derivados de oximas sustituidas utiles como antagonistas de la neuroquinina.
BRPI0410117A (pt)	2006-05-23	composto, composição farmacêutica, método para o tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
EA200301232A1 (ru)	2004-04-29	Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
SE0101675D0 (sv)	2001-05-11	Novel composition
NO331013B1 (no)	2011-09-05	Nye forbindelser som er anti-inflammasjons, immunomodulerende og anti-proliferative midler, anvendelse av forbindelsene samt farmasoytisk preparat
ATE543796T1 (de)	2012-02-15	24-sulfoximine vitamin d3 derivate
DE60015508T2 (de)	2005-04-21	C-16 ungesätigte fp-selektive prostaglandin analoge
ATE443044T1 (de)	2009-10-15	Tace inhibitoren
WO2004054968A3 (en)	2004-10-21	25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
DE60001433D1 (de)	2003-03-27	Alpha, beta-ungesättigte Ketone
NO20050612L (no)	2005-02-03	Pyrrolidinderivater som oksytocinantagonister
DK0996435T3 (da)	2003-01-27	Aminosyrederivater anvendelige til behandling af slagtilfælde
NO983511D0 (no)	1998-07-30	Difenylstilbener som pro-legemidler for COX-2-inhibitorer